SCHEMBL23891981

SCHEMBL23891981

CCNC(CC)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 3/20 0.42
SIGMAR1 Q99720 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
ADRA2C P18825 1/20 0.41
HTR2A P28223 1/20 0.41
SLC6A4 P31645 1/20 0.41
ADRA1A P35348 1/20 0.41
DRD3 P35462 1/20 0.41
OPRK1 P41145 1/20 0.41
HTR2B P41595 1/20 0.41
ALDH1A1 P00352 1/20 0.40
GPR139 Q6DWJ6 1/20 0.39
KCNA5 P22460 1/20 0.39
EEF2K O00418 1/20 0.39
CASR P41180 1/20 0.39
UTS2R Q9UKP6 2/20 0.38
SLC2A1 P11166 1/20 0.37
GPBAR1 Q8TDU6 1/20 0.37
KIF11 P52732 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8286104 0.83 PDE2A (0.43) PDE2ASIGMAR1LMNAHTR2ASLC6A4
SCHEMBL10087177 0.81 PDE2A (0.46) PDE2AALDH1A1GPR139KCNA5EEF2K
SCHEMBL13376374 0.81 PDE2A (0.42) PDE2AALDH1A1GPR139KCNA5EEF2K
SCHEMBL8298546 0.81 PDE2A (0.42) PDE2AALDH1A1GPR139KCNA5EEF2K
SCHEMBL28220660 0.80 HTR2A (0.54) SIGMAR1LMNAMAPTADRA2CHTR2A
SCHEMBL12154076 0.79 PDE2A (0.47) PDE2ASIGMAR1LMNAMAPTADRA2C
SCHEMBL14161448 0.79 PDE2A (0.47) PDE2ASIGMAR1LMNAMAPTADRA2C
SCHEMBL12154088 0.79 PDE2A (0.47) PDE2ASIGMAR1LMNAMAPTADRA2C
SCHEMBL22031965 0.78 PDE2A (0.42) PDE2ASIGMAR1LMNAMAPTADRA2C
SCHEMBL24312242 0.78 PDE2A (0.42) PDE2ASIGMAR1LMNAMAPTADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3177611-B1 OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES NUEVOLUTION AS (DK) 2021-10-06 EP disclosed